KR20200106032A - 단일-도메인 항체-시토신 디아미나제 융합 단백질 - Google Patents

단일-도메인 항체-시토신 디아미나제 융합 단백질 Download PDF

Info

Publication number
KR20200106032A
KR20200106032A KR1020207018591A KR20207018591A KR20200106032A KR 20200106032 A KR20200106032 A KR 20200106032A KR 1020207018591 A KR1020207018591 A KR 1020207018591A KR 20207018591 A KR20207018591 A KR 20207018591A KR 20200106032 A KR20200106032 A KR 20200106032A
Authority
KR
South Korea
Prior art keywords
gly
ser
seq
fusion protein
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207018591A
Other languages
English (en)
Korean (ko)
Inventor
페이-지운 첸
슈-화 리
Original Assignee
상하이 루모사 테라퓨틱스 여우시안공시
루모사 테라퓨틱스 캄파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 루모사 테라퓨틱스 여우시안공시, 루모사 테라퓨틱스 캄파니 리미티드 filed Critical 상하이 루모사 테라퓨틱스 여우시안공시
Publication of KR20200106032A publication Critical patent/KR20200106032A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207018591A 2018-01-04 2019-01-04 단일-도메인 항체-시토신 디아미나제 융합 단백질 Ceased KR20200106032A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862613653P 2018-01-04 2018-01-04
US62/613,653 2018-01-04
PCT/IB2019/000013 WO2019135159A2 (en) 2018-01-04 2019-01-04 Single-domain antibody-cytosine deaminase fusion proteins

Publications (1)

Publication Number Publication Date
KR20200106032A true KR20200106032A (ko) 2020-09-10

Family

ID=67058005

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207018591A Ceased KR20200106032A (ko) 2018-01-04 2019-01-04 단일-도메인 항체-시토신 디아미나제 융합 단백질

Country Status (14)

Country Link
US (2) US20190202931A1 (enExample)
EP (1) EP3735420A4 (enExample)
JP (2) JP2021511013A (enExample)
KR (1) KR20200106032A (enExample)
CN (1) CN112272673A (enExample)
AU (1) AU2019205128A1 (enExample)
BR (1) BR112020013244A2 (enExample)
CA (1) CA3087135A1 (enExample)
IL (1) IL275691A (enExample)
MX (1) MX2020006822A (enExample)
RU (1) RU2020116541A (enExample)
TW (1) TW201932487A (enExample)
WO (1) WO2019135159A2 (enExample)
ZA (1) ZA202003893B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113527497B (zh) * 2020-04-16 2022-06-10 上海洛启生物医药技术有限公司 抗Trop2纳米抗体及其应用
EP4135733A4 (en) 2020-04-17 2024-06-26 University of Cincinnati MODIFIED PROBIOTICS FOR TREATMENT AND IMMUNITY AGAINST VIRUSES
US20240059794A1 (en) * 2020-12-17 2024-02-22 Parasol Biotech Ltd. Gucy2c binding molecules and uses thereof
EP4277934A1 (en) * 2021-01-14 2023-11-22 Institut Curie Her2 single domain antibodies variants and cars thereof
CN118215685A (zh) * 2021-12-27 2024-06-18 山东先声生物制药有限公司 抗gucy2c抗体及其应用
WO2023198008A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Compositions and methods for treating cancer
WO2023198007A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Anti-nectin-4 antibodies and bispecific antibodies
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
AU2023276697A1 (en) * 2022-05-23 2024-12-12 Cereius, Inc. Her2-binding agents and uses thereof
CN116655806B (zh) * 2023-05-31 2024-01-05 四川大学华西医院 包含shp2 c-sh2结构域的靶向her2阳性肿瘤的car-t及制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
JP4733635B2 (ja) * 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
PE20140625A1 (es) * 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
CA2706425A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
MA33256B1 (fr) * 2009-04-01 2012-05-02 Genentech Inc Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
GB201010389D0 (en) * 2010-06-21 2010-08-04 Ist Superiore Sanita Antibody derivatives

Also Published As

Publication number Publication date
JP2021511013A (ja) 2021-05-06
JP2023126935A (ja) 2023-09-12
CN112272673A (zh) 2021-01-26
AU2019205128A1 (en) 2020-07-16
CA3087135A1 (en) 2019-07-11
RU2020116541A (ru) 2022-02-04
IL275691A (en) 2020-08-31
TW201932487A (zh) 2019-08-16
EP3735420A4 (en) 2021-10-06
WO2019135159A2 (en) 2019-07-11
EP3735420A2 (en) 2020-11-11
US20220056149A1 (en) 2022-02-24
US20190202931A1 (en) 2019-07-04
BR112020013244A2 (pt) 2020-12-01
WO2019135159A3 (en) 2020-02-13
RU2020116541A3 (enExample) 2022-02-28
ZA202003893B (en) 2022-11-30
MX2020006822A (es) 2020-09-03

Similar Documents

Publication Publication Date Title
US20220056149A1 (en) Single-domain antibody-cytosine deaminase fusion proteins
JP7861115B2 (ja) 抗体分子及び複合体
US20210346387A1 (en) Antibody conjugates comprising toll-like receptor agonist
JP2024056795A (ja) Ｃｄ７３に対する抗体分子及びその使用
US11466088B2 (en) VEGFR-2 car immune cells to treat cancers
US20200164084A1 (en) Antibody conjugates comprising toll-like receptor agonist and combination therapies
KR20210013165A (ko) GUCY2c에 특이적인 항체 및 이의 용도
US20240189439A1 (en) Antibodies to pmel17 and conjugates thereof
CN112912109A (zh) 通过施用抗her3抗体-药物缀合物治疗her3-突变的癌症
CN116059395A (zh) 用于选择性制造抗体-药物缀合物的方法
TW202200212A (zh) 包含抗-trop-2抗體之抗體藥物結合物
CN118271441A (zh) 制瘤素m受体抗原结合蛋白
US20230053449A1 (en) Dc-sign antibody drug conjugates
EP3904384A1 (en) Fully humanized anti-gitr antibody and preparation method therefor
JP2020506675A (ja) Ｖｅｇｆｒ−２抗体
JP2024517409A (ja) 抗体薬物結合体及びその作成方法
HK40036942A (en) Single-domain antibody-cytosine deaminase fusion proteins
HK40124330A (en) Anti-cd39 antibodies and use thereof
CN118955718A (zh) 抗体药物缀合物及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200626

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211116

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240419

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240621

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20240419

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I